Automated Geriatric Co-Management Program in Older Patients With Solid Mass or Nodule Suspicious for Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03885908 |
Recruitment Status :
Recruiting
First Posted : March 22, 2019
Last Update Posted : December 16, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer | Other: in-person geriatric co-management Other: automated geriatric co-management | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The proposed study is a randomized controlled trial study. |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Feasibility and Effectiveness of Automated Geriatric Co-Management Program on Improving the Perioperative Care of Older Patients With Solid Mass or Nodule Suspicious for Cancer |
Actual Study Start Date : | March 19, 2019 |
Estimated Primary Completion Date : | March 2022 |
Estimated Study Completion Date : | March 2022 |
Arm | Intervention/treatment |
---|---|
Active Comparator: In-person geriatric co-management group
"In-person" geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety.
|
Other: in-person geriatric co-management
The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. "In-person" geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety. |
Experimental: Automated geriatric co-management program group |
Other: automated geriatric co-management
Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention. |
- feasibility of automated geriatric co-management program [ Time Frame: 2 years ]percentage of recommendations that were followed by the surgery team

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Solid mass or nodule suspicious for cancer
- Aged 65 or older
- Being considered for surgical resection of the solid mass or nodule, with anticipated hospital length of stay of at least two days,
- Completed the eRFA per routine care
Exclusion Criteria:
- Unable to read or comprehend English
- Not having a completed electronic Rapid Fitness Assessment within 2 months of surgery**Note) To avoid excluding patients based this item, patients have to complete another eRFA within two months of surgery.
- Being discharged in one day or earlier from the hospital.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03885908
Contact: Armin Shahrokni, MD, MPH | 646-888-3651 | shahroka@mskcc.org | |
Contact: Robert Downey, MD | 212-639-8124 |
United States, New York | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Armin Shahrokni, MD, MPH 646-888-3651 | |
Contact: Robert Downey, MD 212-639-8124 |
Principal Investigator: | Armin Shahrokni, MD, MPH | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT03885908 |
Other Study ID Numbers: |
19-066 |
First Posted: | March 22, 2019 Key Record Dates |
Last Update Posted: | December 16, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org. |
Supporting Materials: |
Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Automated Geriatric Co-Management Program Perioperative Care Solid mass Nodule 19-066 |